This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 6
  • /
  • FDA approves Vanta a recharge-free implantable neu...
News

FDA approves Vanta a recharge-free implantable neurostimulator for chronic pain.- Medtronic

Read time: 1 mins
Published:13th Jun 2021
Medtronic plc announced it has received FDA approval for Vanta, a high performance recharge-free implantable neurostimulator (INS) with a device life that can be optimized up to 11 years.

At comparable settings, the Vanta neurostimulator offers nearly twice the device life than competitive primary cell devices. It also utilizes Medtronic's proprietary AdaptiveStim technology for personalized pain relief that adapts to the patient's movement or body position using a built-in accelerometer. AdaptiveStim technology goes beyond in-office programming by automatically adjusting stimulation to maintain each patient's optimal dose. The Vanta neurostimulator also provides unmatched full-body MRI access with Medtronic SureScan technology. Approximately 82% of SCS-implanted patients will need at least one MRI within five years of implant. "Not every patient with chronic, intractable pain is an ideal candidate for a rechargeable device, so the Vanta INS represents a welcome addition to my portfolio of available treatment options," said Krishnan Chakravarthy, M.D., Ph.D., a San Diego-based interventional pain management physician. "The extended battery life, broad MRI compatibility and personalized relief through AdaptiveStim technology allow for a more hassle-free experience and greater freedom for my patients as we manage their chronic pain."

Condition: Pain: Chronic
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.